For example, oral pills have been used in the diabetes care market for patients with Type Two DM, but its tweaked use for patients with Type One DM has not been fully discovered yet. However, the inhaled insulin brand Exubera was approved by the FDA in late January of 2006 for treatment of adults with type 1 or type 2 diabetes (Inhaled insulin earns FDA approval, 2006). Hopefully these sorts of alternative treatments will gain efficiency and popularity as time passes. Mainstream insulin therapies that do not require frequent injection would make an enormous impact in regard to people who may have trouble giving/receiving injections. Many individuals contend that DM, both Type One and Type Two, does not have a concrete cure; instead, patients who have diabetes would receive care so advanced that there would be little to no lifestyle change after diagnosis. Technologies such as these non-injectable treatments are an integral step toward achieving this
For example, oral pills have been used in the diabetes care market for patients with Type Two DM, but its tweaked use for patients with Type One DM has not been fully discovered yet. However, the inhaled insulin brand Exubera was approved by the FDA in late January of 2006 for treatment of adults with type 1 or type 2 diabetes (Inhaled insulin earns FDA approval, 2006). Hopefully these sorts of alternative treatments will gain efficiency and popularity as time passes. Mainstream insulin therapies that do not require frequent injection would make an enormous impact in regard to people who may have trouble giving/receiving injections. Many individuals contend that DM, both Type One and Type Two, does not have a concrete cure; instead, patients who have diabetes would receive care so advanced that there would be little to no lifestyle change after diagnosis. Technologies such as these non-injectable treatments are an integral step toward achieving this